A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 248 participants.
Also called NCT01609140
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 248 participants
- Sponsor
- Registry
-
NCT01609140
-
- Other papers using this trial's data
- Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study)
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Canada, Czechia, Germany, Hungary, New Zealand, Norway, Slovakia, South Africa
- Registry status
- Completed
Technical summary
Registry record NCT01609140. Randomized; double masking; primary purpose treatment. Start 2012-05 (registry gives no type); primary completion 2013-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease
- Condition
- Coronary Heart Disease
- Intervention (Drug)
- MPSK3169A
- Intervention (Drug)
- MPSK3169A
- Intervention (Drug)
- MPSK3169A
- Intervention (Drug)
- MPSK3169A
- Intervention (Drug)
- MPSK3169A
- Intervention (Drug)
- Placebo
- Lead sponsor
- Genentech, Inc.
Record details
- Record id
cardio:ct-nct01609140- Content hash
ab9d8db4566959aaaf92d1d13a0cc60459c5cb1f8ea432e858e2d5e49a398667